<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83823">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01705249</url>
  </required_header>
  <id_info>
    <org_study_id>KLIM-1408</org_study_id>
    <nct_id>NCT01705249</nct_id>
  </id_info>
  <brief_title>Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women</brief_title>
  <official_title>Bleeding Profile With Continuous Hormone Replacement Therapy in Postmenopausal Women: A Prospective, Open, Multicenter Trial of Activelle® Treatment Following Switch From Trisekvens®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Europe. The aim of this study is to investigate the bleeding
      profile after switch from Trisekvens® to Activelle® (1.0 mg estradiol / 0.5 mg
      norethisterone acetate (NETA)).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Postmenopausal women's acceptance of bleeding</measure>
    <time_frame>After 24 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding profile in postmenopausal women</measure>
    <time_frame>After 24 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptance of hot flushes and breast tenderness</measure>
    <time_frame>After 24 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">191</enrollment>
  <condition>Menopause</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>estradiol / norethisterone acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)</intervention_name>
    <description>After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.</description>
    <arm_group_label>estradiol / norethisterone acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women

          -  At least 3 months on Trisekvens® before screening period

          -  Ability to understand and comply with the protocol requirements

        Exclusion Criteria:

          -  Less than 12 months or more than 36 months postmenopausal judged by the Investigator

          -  Known, suspected, or past history of hormone dependent tumor/cancers

          -  Deep venous thrombosis, active thrombophlebitis, thromboembolic disorders,
             cerebrovascular accidents or past history of these conditions

          -  Ischemic heart disease or myocardial infarction within 6 months prior to
             randomization
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Egil Wickstrøm</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk Scandinavia AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0309</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Södertälje</city>
        <zip>151 23</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 11, 2012</lastchanged_date>
  <firstreceived_date>October 8, 2012</firstreceived_date>
  <responsible_party>
    <name_title>Public Access to Clinical Trials</name_title>
    <organization>Novo Nordisk A/S</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
